Roflumilast Oral Tablet
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebrovascular Disorders
Conditions
Cerebrovascular Disorders, Memory, Functional Recovery, Drug Intervention
Trial Timeline
Jul 7, 2021 → Dec 1, 2023
NCT ID
NCT04854811About Roflumilast Oral Tablet
Roflumilast Oral Tablet is a phase 2 stage product being developed by Brain Biotech for Cerebrovascular Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT04854811. Target conditions include Cerebrovascular Disorders, Memory, Functional Recovery.
What happened to similar drugs?
5 of 7 similar drugs in Cerebrovascular Disorders were approved
Approved (5) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04854811 | Phase 2 | Completed |
Competing Products
14 competing products in Cerebrovascular Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 35 |
| donepezil hcl | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 43 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 30 |
| Abciximab | Eli Lilly | Phase 3 | 32 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 26 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 43 |
| Valsartan | Novartis | Pre-clinical | 18 |
| Atorvastatin | Pfizer | Approved | 43 |
| Rivaroxaban | Bayer | Pre-clinical | 19 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 26 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 40 |
| Atorvastatin 20mg | Brain Biotech | Approved | 40 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 11 |